Monday, 31 August 2026European Markets

EUROAPI Stock Went Down By Over 28% In The Last 21 Sessions

Loading stream...

(vianews) - shares of euroapi (cac 40: eapi.pa) fell by a staggering 28.72% in 21 sessions from €15.6 to €11.12 at 10:54 est on friday, after two successive sessions in a row of losses. cac 40 is rising 0.84% to €7,085.06, following the last session's upward trend.

about euroapi

euroapi sa develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use. it provides contract development manufacturing organization for different classes of tides that uses solid phase chemistry; prostaglandins; steroids & hormones; and opiates and controlled substances. the company was incorporated in 2021 and is headquartered in paris, france.

volume

today's last reported volume for euroapi is 57624 which is 52% below its average volume of 288228.

volatility

euroapi's last week, last month's, and last quarter's current intraday variation average was a negative 1.23%, a negative 2.26%, and a positive 2.08%.

euroapi's highest amplitude of average volatility was 3.17% (last week), 3.43% (last month), and 2.08% (last quarter).

more news about euroapi (eapi.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com